Search results
Results from the WOW.Com Content Network
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
CRISPR Therapeutics reports that it has activated over 35 ATCs and collected cells from 20 patients as of mid-July. The progress is slow. But there's a silver lining once you look at Casgevy's ...
The biotech industry has lagged the broader market so far in 2024. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. CRISPR Therapeutics is a ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $83.39, marking a +1.81% move from the previous day. Skip to main content. 24/7 Help. For premium support please call: 800 ...
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.